A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: Report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Mantz, Constantine ^a  

^a 21ST CENTURY ONCOLOGY   (United States)

Author keywords

Hypofractionation; Prostate cancer; SABR

Indexed keywords

ARTICLE; BLADDER FUNCTION; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE CONTROL; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE FUNCTION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; ORGANS AT RISK; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DETECTION; RADIATION DOSE DISTRIBUTION; REAL TIME TRACKING SYSTEM; SEXUAL FUNCTION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT RESPONSE; URINARY FREQUENCY; URINE INCONTINENCE;

EID: 84928315376     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00279     Document Type: Article

References (37)

1. Available from: https://www.astro.org/uploadedFiles/Main_Site/Practice:Management/Reimbursement/2013HPcoding%20guidelines_SBRT_Final.pdf
2. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys (1999) 43:1095-101. doi: 10.1016/S0360-3016(98)00438-6
3. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low a/ß ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys (2002) 52:6-13. doi:10.1016/S0360-3016(01)02664-5
4. Wang JZ, Guerrero M, Allen LX. How low is the a/ß ratio for prostate cancer? Int J Radiat Oncol Biol Phys (2003) 55:194-203. doi:10.1016/S0360-3016(02)03828-2
5. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys (2003) 56:1093-104. doi:10.1016/S0360-3016(03)00132-9
6. King CR, Fowler JF. A simple analytic derivation suggests that prostate alpha/beta ratio is low. Int J Radiat Oncol Biol Phys (2001) 51:213-4. doi:10.1016/S0360-3016(01)01651-0
7. Fowler J, Chappell R, Ritter M. Is a/ß for prostate tumors really low? Int J Radiat Oncol Biol Phys (2001) 50:1021-31. doi:10.1016/S0360-3016(01)01607-8
8. Brenner DJ. Toward optimal external-beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys (2000) 48:315-6. doi:10.1016/S0360-3016(00)00591-5
9. Duschesne GM, Peters LJ. What is the a/ß ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys (1999) 44:747-8.
10. Ritter M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol (2008) 18:249-56. doi:10.1016/j.semradonc.2008.04.007
11. Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol (2008) 18:240-3. doi:10.1016/j.semradonc.2008.04.005
12. Park C, Papiez S, Zhang M, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys (2008) 70:847-52. doi:10.1016/j.ijrobp.2007.10.059
13. Byrne TE. A review of prostate motion with considerations for the treatment of prostate cancer. Med Dosim (2005) 30:155-61. doi:10.1016/j.meddos.2005.03.005
14. Kitamura K, Shirato H, Seppenwoolde Y, Onimaru R, Oda M, Fujita K, et al. Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions. Int J Radiat Oncol Biol Phys (2002) 53:1117-23. doi:10.1016/S0360-3016(02)02882-1
15. Britton KR, Takai Y, Mitsuya M, Nemoto K, Ogawa Y, Yamada S. Evaluation of inter- and intrafraction organ motion during intensity modulated radiation therapy (IMRT) for localized prostate cancer measured by a newly developed on-board image-guided system. Radiat Med (2005) 23:14-24.
16. Huang E, Dong L, Chandra A, Kuban DA, Rosen II, Evans A, et al. Intrafraction prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys (2002) 53:261-8. doi:10.1016/S0360-3016(02)02738-4
17. Nederveen AJ, van derHeide UA, Dehnad H, van Moorselaar RJ, Hofman P, Lagendijk JJ. Measurements and clinical consequences of prostate motion during a radiotherapy fraction. Int J Radiat Oncol Biol Phys (2002) 53:206-14. doi:10.1016/S0360-3016(01)02823-1
18. Hossain S, Xia P, Chuang C, Verhey L, Gottschalk AR, Mu G, et al. Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Med Phys (2008) 35:4041-8. doi:10.1118/1.2968333
19. Boike T, Anderson J, Novotny J, Abdulrahman R, Pistenmaa D, Timmerman R. Intra-fraction and inter-fraction prostate motion associated with stereotactic body radiation therapy (SBRT) and image guided radiation therapy (IGRT). Int J Radiat Oncol Biol Phys (2007) 69:S355. doi:10.1016/j.ijrobp.2007.07.1446
20. Kupelian P, Willoughby T, Mahadevan A, Djemil T, Weinstein G, Jani S, et al. Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys (2007) 67:1088-98. doi:10.1016/j.ijrobp.2006.10.026
21. Kitamura K, Shirato H, Shinohara N, Harabayashi T, Onimaru R, Fujita K, et al. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor tracking system for prostate cancer: Preliminary results of a phase I/II study. Cancer J (2003) 9:268-76. doi:10.1097/00130404-200307000-00009
22. Cheung P, Sixel K, Morton G, Loblaw DA, Tirona R, Pang G, et al. Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer. Int J Radiat Oncol Biol Phys (2005) 62:418-25. doi:10.1016/j.ijrobp.2004.09.051
23. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Lancet Oncol (2012) 13:43-54. doi:10.1016/j.ijrobp.2007.10.004
24. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys (2005) 63:1463-8. doi:10.1016/j.ijrobp.2005.05.054
25. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: the Cleveland Clinic experience. Int J Radiat Oncol Biol Phys (2007) 68:1424-30. doi:10.1016/j.ijrobp.2007.01.067
26. Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomized controlled trial. Lancet Oncol (2012) 13:43-54. doi:10.1016/S1470-2045(11)70293-5
27. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionated versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2010) 78:11-8. doi:10.1016/j.ijrobp.2009.07.1691
28. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 31:1-11. doi:10.1200/JCO.2013.51.1972
29. Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys (2014) 88:1074-84. doi:10.1016/j.ijrobp.2014.01.015
30. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol (2010) 10:1. doi:10.1186/1471-2490-10-1
31. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in 5 fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys (2007) 67:1099-105. doi:10.1016/j.ijrobp.2006.10.050
32. Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS, et al. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk prostate cancer: early results of pHART3. Clin Oncol (2008) 20:729-37. doi:10.1016/j.clon.2008.08.006
33. King CR, Brooks JD, Gill H, Presti JCJr. Long term outcomes from a prostatecive trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2012) 82:877-82. doi:10.1016/j.ijrobp.2010.11.054
34. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-instituional phase I feasibility trial. Cancer (2012) 118:3681-90. doi:10.1002/cncr.26699
35. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol (2011) 29:2020-6. doi:10.1200/JCO.2010.31.4377
36. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol (2013) 109:217-21. doi:10.1016/j.radonc.2013.08.030
37. King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys (2013) 87:939-45. doi:10.1016/j.ijrobp.2013.08.019